Optimal Dosing of 5-Aminosalicylic Acid: 5 Decades of Choosing Between Politicians

The right dose differentiates a poison and a remedy.

— Paracelsus

5-Aminosalicylic acid (mesalamine) delivered to the colon by sulfasalazine (SASP) was advanced as therapy for ulcerative colitis (UC) in 1952.[1] Mesalamine and SASP are effective in the induction and maintenance of remission in UC; this is robustly supported by placebo- controlled trials. Unfortunately, however, the story of the mesalamine delivery systems and recommended doses from 1952 to the present time has not followed a logical, step-wise evolution to an ideal approach but rather resembles a series of political campaigns. As Otto von Bismarck, the Prussian statesman, stated in 1863, “Politics is not an exact science.” It is common practice to lump mesalamine preparations together but to consider them separately from SASP. Within the mesalamine class, we have been presented with a variety of products: arrays of paired active molecules; prodrugs, custom-designed coatings; specialized granule design. Differences in the chemistry, delivery systems, and bioavailability of these specific products have made it diffi- cult to sort out whether mesalamine is truly superior to SASP and more specifically whether a particular mesalamine delivery system is best.

“More is better” is a central theme and is based on the dose-response relationship observed with SASP in doses up to 4 g/day.[2] Many clinicians have used upward titration of SASP to the highest tolerated dose to induce remission followed by downward titration to a dose that minimized side effects for long-term maintenance therapy. In clinical practice, this strategy has been applied to various mesalamine preparations for which on careful scrutiny of the available data, a dose-response relationship may not be so clear.

A systematic review of mesalamine for the induction of remission in UC found only a trend to a significant dose response.[3] In the PROBE trial examining type and dose of mesalamine for maintenance of remission in 388 patients with UC, mesalamine as Asacol 2 g/day and Salofalk 2 g/day showed equivalence, and no additional benefit was seen from higher dosing with 3.2 g of Asacol.[4]

In this issue of Clinical Gastroenterology and Hepatology, Kruis et al.5 describe their experience in an international industry-funded investigation of one of the latest candidate mesalamine agents. They examined the efficacy of a new mesalamine pellet preparation administered as a sachet 3 times daily in equal doses for 8 weeks. These pellets are designed to offer both delayed and sustained release to target the colon. Three hundred nineteen patients were randomized to daily dosing with 1.5, 3.0, or 4.5 g. The primary end point was clinical remission rate at 8 weeks, and the study was powered accordingly. At 8 weeks, all groups had similar remission and improvement rates, with clinical remission ranging from 50% to 60%. They conclude that there is no significant dose response between 1.5, 3, or 4.5 g per day and suggest that the optimal dose for mesalamine is 0.5 g 3 times a day (1.5 g).

Kruis et al. are to be praised for controlling concomitant medications, choosing a primary end point, performing a power analysis, and then faithfully reporting the outcome of the study. Unfortunately, their conclusions do not end the debate over dose-response curves for this class of drugs. For example, in this particular trial, the clinician and patient will also be interested in more details of the median time to onset of action for each treatment arm. Most would concur that suffering 26 days of diarrhea (as was seen in the group randomized to 1.5 g per day) would be worse than the 15 days of diarrhea observed in the highest dose group. The study subjects seemed to agree that this outcome was important; many voted with their feet, with 23% dropping out most often for “inefficiency of treatment” in the lowest dose group compared to 10% in the 4.5-g dose group. The 1.5-g dose group also suffered more adverse events than the higher dose groups, presumably because of classification of inefficiency of treatment as an adverse event. In addition, this study does not answer the question of whether patients treated with 1.5 or 3.0 g/day who fail to respond then subsequently respond if the mesalamine dose is escalated to 4.5 g/day.

How should the clinicians incorporate the information from this study into their practice? We suggest that they look at these data carefully. With further investigation of this agent, it is likely that there will be differences demonstrated between efficacy, where conclusions are made in the controlled construct of a study, and effectiveness, where conclusions are drawn from how an agent performs in clinical practice. For this particular delivery system (specialized pellets administered as a sachet) in a controlled trial setting (8-week observation period), the difference in clinical remission rates between doses was not significant. In practice, the relatively large number of pills required for the recommended dose of many of the commercial products in this class and the patient’s inclination to opt for speedier (albeit more toxic) agents will also influence our perception of the candidate medication. In the meantime, this particular campaign reminds us to continue to question whether more is truly better. As we embrace information based on evidence, we should avoid falling into the trap of practical politics and heed the admonition of the U.S. historian Henry Adams, “Practical politics consists in ignoring facts.”

STEPHEN J . BICKSTON, M.D. FABIO COMINELLI, M.D., PH.D.

University of Virginia Digestive Health Center of Excellence Charlottesville, Virginia

References

1. Morrison LM. Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology 1952;21:133– 138.

2. Hanauer SB. Aminosalicylates therapy for ulcerative colitis. In: Bayless TM, Hannauer SB, eds. Advanced therapy of in- flammatory bowel disease. 2nd ed. Hamilton, Ontario: B. C. Decker, 2001.

3. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2002;3:CD000543.

4. Deventer SJH, Hommes DW, Roskam Mul MDM, Dekker W, Wetzels A, Nelis F, Engels Z, Snel P, Schook G, Meuwissen SGM, Tytgat GNJ. Prospective randomized open-label blinded endpoint (PROBE) trial of high- versus low-dose mesalazine for prevention of relapse in patients with ulcerative colitis in remission (abstr). Gastroenterology 2001; 120:A454.

5. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Arber N, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R, for the International Salofalk Pellets Study Group. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36–43.

News about Crohn's Disease

Channel: Crohn's News From Medical News Today

• NICE Recommends Infliximab And Adalimumab For The Treatment Of Severe, Active Crohn's Disease

In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn's disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy...
• Thiopurine Therapy For IBD Improves Quality Of Life

Patients with inflammatory bowel diseases (IBDs) such as Crohn's disease or ulcerative colitis do perceive a benefit from thiopurine treatment. A report in the open access journal BMC Gastroenterology has demonstrated improved health-related quality of life in 92 IBD patients...
• Behavioral Health Registry For Pediatric Inflammatory Bowel Disease To Be Created With NIH Grant

The National Institutes of Health has awarded a two-year development grant to researchers with Hasbro Children's Hospital and the Bradley Hasbro Children's Research Center to better understand the role behavioral health plays in pediatric inflammatory bowel disease (IBD), a condition that causes chronic and painful inflammation in the gastrointestinal tract...
• Protein Found To Be Key In Protecting The Gut From Infection

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe...
• New Guideline Identifies Major Risk Factors In The Development Of Colorectal Cancer In Children And Adults With Inflammatory Bowel Disease

Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD...
• Distinct Demographic Profiles Between Crohn's Disease And Ulcerative Colitis

Although inflammatory bowel disease (IBD) [comprising mainly Crohn's disease (CD) and ulcerative colitis (UC)] is thought to affect about 150 000 people in the United Kingdom, the prevalence of severe IBD is not known. Mortality following hospitalization for IBD is significant but little has been reported on long-term follow-up...
• Sufferers Of Crohn's Disease May Benefit From Vitamin D Supplements

A new study has found that Vitamin D, readily available in supplements or cod liver oil, can counter the effects of Crohn's disease...
• Promising Probiotic Treatment For Inflammatory Bowel Disease

Bacteria that produce compounds to reduce inflammation and strengthen host defences could be used to treat inflammatory bowel disease (IBD). Such probiotic microbes could be the most successful treatment for IBD to date, as explained in a review published in the February issue of the Journal of Medical Microbiology...
• GSK Exercises Option To Progress Development Of ChemoCentryx's Traficet-EN For The Treatment Of Inflammatory Bowel Diseases

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease...
• Clinical Trial Seeks To Improve Patient Treatment For Crohn's Disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease. The outcome is expected to lead to a more streamlined treatment path and better disease management for patients...
• Cancer/Inflamation Link Discovered By University Of Montreal

Canadian researchers have discovered a novel molecular mechanism that prevents cancer...
• Cedars-Sinai IBD Expert Awarded Inaugural Endowed Chair

Marla C. Dubinsky, M.D., director of the Cedars-Sinai Pediatric Inflammatory Bowel Disease Center and one of the world's leading researchers studying the disease, has been named the Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease. The endowed chair, presented in November, will fund continuing research to find groundbreaking new treatments for IBD...
• ChemoCentryx Reports Positive PROTECT-1 Study Results For Traficet-EN(TM) At The GASTRO 2009 UEGW/WCOG Conference

ChemoCentryx, Inc., announced that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile...
• Thalidomide: Solving The 50-Year-Old Puzzle

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues...
• Subset Data From Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates Of Hospitalization In Patients With Crohn's Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate - to - severe Crohn's disease during both induction and maintenance treatment...
• Probiotic Found To Be Effective Treatment For Colitis In Mice

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment...
• Biomedical Research Centre Searches For Immunological Biomarkers

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection...
• Diagnosis And Treatment Of Inflammatory Bowel Disease Should Improve Following Discovery Of Genetic Defect

New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease (IBD), the most common chronic gastrointestinal illness in children and teens. Two million Americans have IBD which involves inflammation of the gastrointestinal tract...
• Wildlife As A Source For Livestock Infections

A bacterium possibly linked to Crohn's disease could be lurking in wild animals. According to research published in the open access journal BMC Microbiology, Mycobacterium avium subspecies paratuberculosis (Map), can be transmitted between wildlife and domestic ruminants, supporting the theory of wildlife reservoirs of infection...
• What Is Bowel Incontinence? What Is Fecal Incontinence? What Causes Bowel Incontinence?

Bowel incontinence, also known as fecal (UK: faecal) incontinence, is an inability to control bowel movements. The person's stools (feces) leak from the rectum uncontrollably. Bowel incontinence can vary in severity from passing a small amount of feces when breaking wind, to total loss of bowel control...
• What Is Ulcerative Colitis? What Causes Ulcerative Colitis?

Ulcerative colitis is a fairly common chronic (long-term) disease that causes inflammation of the colon (the large intestine). It is a form of inflammatory bowel disease that has some similarity to Crohn's disease, a related disorder. The colon - or large intestine - removes nutrients form undigested food and gets rid of waste products through the rectum and anus when we pass feces (stools)...
• Antimicrobial Antibodies In Celiac Disease: Trick Or Treat?

Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet...
• FDA: Cancer Warnings Required For TNF Blockers

The U.S. Food and Drug Administration is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers...
• Predictors Of Disease Behavior Change In Crohn's Disease

Using the Vienna classification system, it has been shown in clinic-based cohorts that there can be a significant change in disease behavior over time, whereas disease location remains relatively stable. Clinical and environmental factors as well as medical therapy might be relevant in predicting disease behavior change in patients with CD...
• What Is Diarrhea? What Causes Diarrhea?

Diarrhea is the frequent passing of loose or watery stools. Acute diarrhea, which is a common cause of death in developing countries, appears rapidly and may last from five to ten days. Chronic diarrhea lasts much longer and is the second cause of childhood death in the developing world. Diarrhea is sometimes accompanied by abdominal cramps or fever...